Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data
Bio Expo
Champignondagen
  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • News

Exelixis: Zanzalintinib Combo Boosts Survival in Phase 3 Colorectal Cancer Trial

  • The Pharma Data
  • June 23, 2025

Exelixis Reports Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combo in Metastatic Colorectal Cancer Exelixis, has announced promising topline results from the STELLAR-303 phase 3 pivotal clinical trial, a…

Read MoreExelixis: Zanzalintinib Combo Boosts Survival in Phase 3 Colorectal Cancer Trial
  • News

CHMP Recommends EU Approval of Sarclisa for Newly Diagnosed Multiple Myeloma

  • The Pharma Data
  • June 23, 2025

Sarclisa Moves Closer to EU Approval for Frontline Treatment of Transplant-Eligible Multiple Myeloma Patients The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive…

Read MoreCHMP Recommends EU Approval of Sarclisa for Newly Diagnosed Multiple Myeloma
  • News

Roche’s NXT007 Shows Early Promise for Normalising Clotting in Haemophilia A

  • The Pharma Data
  • June 23, 2025

Roche Unveils Promising Phase I/II Data for Next-Generation Bispecific Antibody NXT007 in Hemophilia A, Signaling a Major Step Toward Phase III Development Roche has shared encouraging new data from its…

Read MoreRoche’s NXT007 Shows Early Promise for Normalising Clotting in Haemophilia A
  • News

Novo Nordisk’s CagriSema Shows 22.7% Weight Loss in REDEFINE 1 Study Published in NEJM

  • The Pharma Data
  • June 23, 2025

Novo Nordisk’s CagriSema Delivers Up to 22.7% Weight Loss in Obese or Overweight Adults, REDEFINE 1 Trial Results Published in NEJM In a significant advancement for the treatment of obesity…

Read MoreNovo Nordisk’s CagriSema Shows 22.7% Weight Loss in REDEFINE 1 Study Published in NEJM
  • News

Novo Nordisk: Phase 3 Data Shows Mim8 Well-Tolerated After Switch from Emicizumab in Hemophilia A

  • The Pharma Data
  • June 23, 2025

Novo Nordisk Unveils Positive Phase 3b Results for Mim8 in Hemophilia A: Seamless Switch from Emicizumab Shows Safety, Efficacy, and High Patient Satisfaction Novo Nordisk presented new findings from its…

Read MoreNovo Nordisk: Phase 3 Data Shows Mim8 Well-Tolerated After Switch from Emicizumab in Hemophilia A
  • News

CHMP Recommends Third Indication for Bayer’s Nubeqa in Advanced Prostate Cancer Patients

  • The Pharma Data
  • June 21, 2025

CHMP Recommends Expanded Use of Bayer’s Nubeqa™ (Darolutamide) for Advanced Prostate Cancer Following Positive ARANOTE Trial Results The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…

Read MoreCHMP Recommends Third Indication for Bayer’s Nubeqa in Advanced Prostate Cancer Patients
  • NewsResearch

Vertex Reports Favorable Zimislecel Outcomes for Type 1 Diabetes at ADA Scientific Sessions

  • The Pharma Data
  • June 21, 2025

Vertex Showcases Groundbreaking Data for Zimislecel in Type 1 Diabetes at ADA 85th Scientific Sessions Vertex Pharmaceuticals Incorporated has announced compelling new clinical data from its ongoing FORWARD-101 trial, underscoring…

Read MoreVertex Reports Favorable Zimislecel Outcomes for Type 1 Diabetes at ADA Scientific Sessions
  • News

FDA Approves Dupixent as First and Only Targeted Therapy for Bullous Pemphigoid in the US

  • The Pharma Data
  • June 21, 2025

FDA Approves Dupixent as the First and Only Targeted Therapy for Adults with Bullous Pemphigoid In a groundbreaking development for patients suffering from a rare and debilitating autoimmune skin disease,…

Read MoreFDA Approves Dupixent as First and Only Targeted Therapy for Bullous Pemphigoid in the US
  • News

Combination of Lunsumio and Polivy from Roche Significantly Extends Remission in R/R Large B-Cell Lymphoma

  • The Pharma Data
  • June 21, 2025

Roche’s Lunsumio and Polivy Combination Marks Major Advance in Relapsed or Refractory Large B-Cell Lymphoma with Significant Remission Durability Roche has announced promising results from its pivotal Phase III SUNMO…

Read MoreCombination of Lunsumio and Polivy from Roche Significantly Extends Remission in R/R Large B-Cell Lymphoma
  • Press Releases

H20 Summit to Shape G20 Health Agenda and Financing

  • The Pharma Data
  • June 20, 2025

Rebuilding Trust and Reshaping Global Health Finance: H20 Summit Lays Groundwork for G20 Health Agenda From June 19 to 20, global leaders in health and development converged in Geneva for…

Read MoreH20 Summit to Shape G20 Health Agenda and Financing
  • News

Civil Society Drives Global Health Agenda at WHA78

  • The Pharma Data
  • June 20, 2025

Civil Society Deepens Its Role in Shaping Global Health Policy at WHA78 At the 78th World Health Assembly (WHA78), held under the unifying theme “One World for Health,” a pivotal…

Read MoreCivil Society Drives Global Health Agenda at WHA78
  • News

Grifols’ Fibrinogen Phase 3 Results Published in eClinicalMedicine

  • The Pharma Data
  • June 20, 2025

Grifols’ BT524 Fibrinogen Therapy Shows Promise in Phase 3 Trial Published in The Lancet’s eClinicalMedicine Grifols, a globally recognized healthcare company and a leader in the production of plasma-derived therapies,…

Read MoreGrifols’ Fibrinogen Phase 3 Results Published in eClinicalMedicine
PrevNext
UK Biotech Day
Global Clinical
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Curi Bio and Battelle Partner to Advance Neuromuscular Pharmacology Innovations
  • ImmunityBio Secures Macau Approval for ANKTIVA® to Treat BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors
  • KalVista to Showcase New EKTERLY® Data at 2026 Global Angioedema Conference
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.